ADAM-28 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAM-28 (UniProt Q9UKQ2), expressed in HEK293 cells. Suited for metalloprotease activity assays, ectodomain shedding studies, inhibitor IC50 determination, and antibody validation.
Expression system
HEK293
Cat. #
REC-ADAM28

In stock

SKU
REC-ADAM28
$498.00

Target Overview

ADAM-28 (UniProt Q9UKQ2; gene: ADAM28) is a member of the ADAM (a disintegrin and metalloproteinase) family of zinc-dependent proteases. The full-length human protein spans 775 amino acids and is annotated as a membrane-anchored metalloprotease, though a secreted splice form (ADAM28s) has been characterised in published literature. Like other ADAMs, the domain architecture includes a prodomain, a catalytic metalloprotease domain (EC 3.4.24.-), a disintegrin-like domain, a cysteine-rich region, and a transmembrane anchor, making it structurally suited for both substrate cleavage and cell-surface adhesive interactions. This recombinant is produced in HEK293 cells, providing mammalian-type glycosylation and disulfide bond formation that are relevant to the native conformation of the metalloprotease and disintegrin domains. Researchers select HEK293-expressed ADAM family members specifically because prokaryotic and insect-cell systems frequently yield misfolded or poorly active protease domains. In the laboratory, recombinant ADAM-28 is used primarily in three categories of experiment: (1) enzymatic activity assays measuring cleavage of candidate substrates such as IL-6 receptor (IL6R), FASL, and CD40L ectodomains; (2) inhibitor screens and IC50 determination against small-molecule or peptide-based metalloprotease inhibitors; and (3) antibody validation, where the recombinant serves as a well-defined positive control antigen in Western blot and ELISA formats. Researchers requiring a validated detection reagent for their ADAM-28 studies can pair this recombinant with the matched Triple Point Biologics antibody (SKU: RP-ADAM28), which has been validated for Western blot against human targets.

Background

ADAM-28 is a disintegrin and metalloproteinase family member with expression documented prominently in lymphoid tissues and the male reproductive tract, where it has been investigated in the context of sperm maturation and epididymal biology. Its proposed biological roles span two distinct areas: ectodomain shedding of lymphocyte surface proteins — including FASL and CD40L — and adhesive functions that may contribute to lymphocyte trafficking across vascular barriers. The secreted form, ADAM28s, is generated by alternative splicing and lacks the transmembrane anchor, and has been the focus of recent oncology-oriented research. The protease has been studied as a research target in multiple malignancy contexts. Zhao et al. (2025, Discov Oncol) provide a systematic review of ADAM28 expression and functional data across malignant tumour types, consolidating published evidence on its roles in tumour cell proliferation, invasion, and substrate-mediated signalling. In esophageal squamous cell carcinoma, Kouzu et al. (2025, Lab Invest) report increased expression of the secreted ADAM28s isoform and describe a mechanism linking IL-6 receptor shedding by ADAM28s to downstream proliferative signalling — a finding with direct relevance for researchers designing substrate cleavage or receptor shedding assays with this recombinant. ADAM28 has also appeared in genomics-based target identification studies in multiple myeloma (Liu et al., 2025, Genome Med), illustrating its continued utility as a research target in haematological malignancy models. In the neuroinflammation field, ADAM28 is among the proteases and immunomodulatory molecules examined in studies of mesenchymal stem cell behaviour in multiple sclerosis (Tanasescu et al., 2025, Neurol Neuroimmunol Neuroinflamm). Independently, its expression in male reproductive tissue has been referenced in spermiogenesis gene-function studies (Du et al., 2025, Reprod Biol). For researchers designing in vitro protease experiments, this recombinant is relevant for: characterising substrate specificity using synthetic peptides or ectodomain fragments of known targets; benchmarking inhibitor potency across the ADAM family; and producing defined antigen preparations for antibody calibration. Because ADAM-28 is expressed at the cell surface and in soluble secreted form depending on the splice variant, the HEK293-expressed recombinant provides a physiologically relevant protein fold for both biochemical and cell-free shedding assays.

Applications

  • Metalloprotease activity assay using fluorogenic peptide substrates (e.g., Mca-RPPGFSAFK(Dnp) or analogues)
  • Ectodomain shedding assay measuring IL-6 receptor (IL6R) cleavage in cell-free format
  • Small-molecule inhibitor IC50 determination against the ADAM-28 catalytic domain
  • Substrate identification by mass spectrometry using recombinant ADAM-28 and candidate ectodomain fragments
  • Positive control antigen for Western blot calibration and band-size confirmation (~775 aa full-length)
  • ELISA standard curve preparation for quantification of ADAM-28 in conditioned media or tissue lysates
  • Antibody validation paired with Triple Point Biologics anti-ADAM-28 antibody (SKU: RP-ADAM28) by Western blot or dot blot
  • Surface plasmon resonance or biolayer interferometry binding studies with candidate inhibitors or disintegrin-domain ligands

References

  1. Zhao L et al. Research progress on ADAM28 in malignant tumors. Discov Oncol. 2025. doi:10.1007/s12672-025-02342-4. PMID: 40252142.
  2. Kouzu K et al. Increased Expression of Secreted Form A Disintegrin and Metalloproteinase 28 (ADAM28s) in Esophageal Squamous Cell Carcinoma: Implication for Carcinoma Cell Proliferation via Interleukin 6 Receptor Shedding. Lab Invest. 2025. doi:10.1016/j.labinv.2025.104222. PMID: 40744225.
  3. Liu E et al. Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups. Genome Med. 2025. doi:10.1186/s13073-025-01503-y. PMID: 40665393.
  4. Tanasescu R et al. Proinflammatory Effect of Mesenchymal Stem Cells From Patients With Multiple Sclerosis: Potential Modulation Targets. Neurol Neuroimmunol Neuroinflamm. 2025. doi:10.1212/NXI.0000000000200444. PMID: 40875958.
  5. Du S et al. Testis-specific gene C3ORF22/BC048671 is dispensable for spermiogenesis and male fertility. Reprod Biol. 2025. doi:10.1016/j.repbio.2025.101089. PMID: 41076814.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface; Golgi → endosomes

Frequently Asked Questions

What molecular weight band should I expect for recombinant ADAM-28 on SDS-PAGE or Western blot?

The full-length human ADAM-28 protein has a predicted molecular weight of ~88 kDa from sequence alone, but the HEK293-expressed recombinant typically migrates at approximately 90–100 kDa under reducing SDS-PAGE conditions due to mammalian N-linked glycosylation. The prodomain is retained in some preparations; if your lot is the processed, prodomain-cleaved form, you may observe a band closer to 65–70 kDa corresponding to the mature metalloprotease/disintegrin fragment. Check your Certificate of Analysis for the specific processed state of your lot. Our matched antibody RP-ADAM28 resolves both forms cleanly on Western blot.

Is Triple Point Biologics recombinant ADAM-28 the full-length form or the secreted ADAM-28s splice variant?

This product (REC-ADAM28) is produced as the catalytic ectodomain fragment encompassing the prodomain through the cysteine-rich region, which corresponds functionally to the secreted ADAM28s splice variant that is detectable in plasma and lymphocyte supernatants. It does not include the transmembrane or cytoplasmic tail. This makes it directly comparable to the secreted isoform used in substrate-cleavage and shedding assays. If your experiment requires the membrane-anchored context, a cell-overexpression model would be more appropriate than this recombinant.

What substrates does recombinant ADAM-28 cleave and how do I set up an activity assay?

ADAM-28 cleaves myelin basic protein (MBP) and has well-documented sheddase activity toward IGFBP-3 and VLA-4 (α4-integrin ectodomain). For a fluorogenic activity assay, a generic ADAM substrate such as Mca-KPLGL-Dpa-AR-NH2 is functional, though ADAM-28 shows relatively modest activity on pan-ADAM peptides compared to ADAM-10/17. A practical starting condition: 200–500 ng recombinant ADAM-28 per 50 µL reaction in 25 mM Tris-HCl pH 7.5, 5 mM CaCl2, 0.1% Brij-35 at 37°C, reading fluorescence at Ex/Em 320/405 nm. Include 10 mM EDTA as a negative control to confirm metal-dependence.

What buffer is recombinant ADAM-28 supplied in and does it interfere with downstream enzymatic assays?

REC-ADAM28 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2. The glycerol stabilises the metalloprotease fold during freeze-thaw but should be diluted to ≤1% in activity assays to avoid viscosity-related artifacts. The 5 mM CaCl2 is compatible with standard ADAM assay buffers; no calcium chelation step is needed. If your assay buffer uses HEPES instead of Tris, a 1:10–1:20 dilution into HEPES-based assay buffer is generally sufficient to reduce Tris carry-over below interference thresholds. Avoid adding EDTA or EGTA to working dilutions, as these will chelate the catalytic zinc.

What starting concentration of recombinant ADAM-28 should I use for IC50 inhibitor screening?

For inhibitor IC50 determination against a fluorogenic substrate, we recommend titrating REC-ADAM28 between 50–200 ng per 50 µL reaction to identify a concentration that produces a linear signal increase over 30–60 minutes, staying well below substrate depletion. Using the lowest enzyme concentration that gives a robust signal improves sensitivity for tight-binding inhibitors (Ki < 10 nM). Broad-spectrum metalloprotease inhibitors such as GM6001 (10 µM) serve as a reliable positive inhibition control. Pre-incubate enzyme with inhibitor for 15 minutes at room temperature before adding substrate.

Can I use Triple Point Biologics recombinant ADAM-28 as a Western blot positive control with the matched RP-ADAM28 antibody?

Yes — this is one of the primary validated uses of REC-ADAM28. The matched rabbit polyclonal RP-ADAM28 (/anti-adam-28-rabbit-polyclonal-antibody) was raised and validated in the same laboratory and is guaranteed compatible with this recombinant for Western blot. Load 10–50 ng of REC-ADAM28 per lane alongside your cell lysate samples. This loading range produces a strong, clean band that confirms antibody performance and molecular weight calibration in the same blot, without overloading lanes adjacent to lower-expressing biological samples.

How much recombinant ADAM-28 should I load for a Western blot positive control and what band size should I expect?

Load 20–50 ng per lane as a positive control when using RP-ADAM28 at its recommended working dilution (typically 1:500–1:2000; confirm on the antibody datasheet). Under reducing conditions, expect the primary band at 90–100 kDa for the glycosylated ectodomain form. A faint lower band near 65–70 kDa may appear if partial prodomain processing occurred. Both bands are recognised by RP-ADAM28. Running this recombinant alongside MCF-7 or Raji cell lysates — cell lines with documented endogenous ADAM-28 expression — provides a useful side-by-side confirmation of endogenous versus recombinant protein migration.

How should I handle, dilute, and store recombinant ADAM-28 to maintain activity after receiving it?

Upon receipt, briefly centrifuge the vial and place immediately at -20°C. REC-ADAM28 is shipped as single-use aliquots to eliminate repeated freeze-thaw, which progressively denatures the metalloprotease active site. Avoid storing working dilutions at 4°C for more than 24 hours. For assay setup, thaw on ice, dilute into cold assay buffer containing 5 mM CaCl2, and use within 2 hours of thawing. Do not vortex; mix gently by pipetting. Adding 0.1% BSA (protease-free) to dilution buffer helps minimise adsorptive losses when working at concentrations below 50 ng/µL.

Validation imagery coming soon

Western blot validation figures for REC-ADAM28 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →